BRPI1007817A2 - composto, composição farmacêutica, uso de um composto, e , métodos para tratar déficit congnitivo na esquisofrenia, doença de alzheimer, obesidade, narcolepsia, dor e distúrbio de hiperatividade e déficit de atenção em um animal de sangue quente, e para tratar um distúrbio em que a modulação do receptor da histamina h3 é benéfica. - Google Patents

composto, composição farmacêutica, uso de um composto, e , métodos para tratar déficit congnitivo na esquisofrenia, doença de alzheimer, obesidade, narcolepsia, dor e distúrbio de hiperatividade e déficit de atenção em um animal de sangue quente, e para tratar um distúrbio em que a modulação do receptor da histamina h3 é benéfica.

Info

Publication number: BRPI1007817A2
Authority: BR; Brazil
Prior art keywords: compound; treating; disorder; schisophrenia; narcolepsy
Prior art date: 2009-02-20

Application number

BRPI1007817A

Other languages

English (en)

Inventor

Griffin Andrew

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-20

Filing date

2010-02-19

Publication date

2017-05-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42631518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1007817(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-19 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2017-05-30 Publication of BRPI1007817A2 publication Critical patent/BRPI1007817A2/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hematology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Psychology (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

BRPI1007817A 2009-02-20 2010-02-19 composto, composição farmacêutica, uso de um composto, e , métodos para tratar déficit congnitivo na esquisofrenia, doença de alzheimer, obesidade, narcolepsia, dor e distúrbio de hiperatividade e déficit de atenção em um animal de sangue quente, e para tratar um distúrbio em que a modulação do receptor da histamina h3 é benéfica. BRPI1007817A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15406709P	2009-02-20	2009-02-20
PCT/SE2010/050191 WO2010096011A1 (en)	2009-02-20	2010-02-19	Cyclopropyl amide derivatives targeting the histamine h3 receptor

Publications (1)

Publication Number	Publication Date
BRPI1007817A2 true BRPI1007817A2 (pt)	2017-05-30

Family

ID=42631518

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007817A BRPI1007817A2 (pt)	2009-02-20	2010-02-19	composto, composição farmacêutica, uso de um composto, e , métodos para tratar déficit congnitivo na esquisofrenia, doença de alzheimer, obesidade, narcolepsia, dor e distúrbio de hiperatividade e déficit de atenção em um animal de sangue quente, e para tratar um distúrbio em que a modulação do receptor da histamina h3 é benéfica.

Country Status (39)

Country	Link
US (3)	US8993577B2 (pt)
EP (1)	EP2398780B1 (pt)
JP (2)	JP5666480B2 (pt)
KR (1)	KR20110126628A (pt)
CN (2)	CN104398516A (pt)
AR (1)	AR075531A1 (pt)
AU (1)	AU2010216454B2 (pt)
BR (1)	BRPI1007817A2 (pt)
CA (1)	CA2752796A1 (pt)
CO (1)	CO6400219A2 (pt)
CR (1)	CR20110447A (pt)
CU (2)	CU20110161A7 (pt)
DK (1)	DK2398780T3 (pt)
DO (1)	DOP2011000270A (pt)
EA (2)	EA020093B1 (pt)
EC (1)	ECSP11011280A (pt)
ES (1)	ES2416464T3 (pt)
HK (1)	HK1208348A1 (pt)
HN (1)	HN2011002261A (pt)
HR (1)	HRP20130579T1 (pt)
IL (1)	IL214277A (pt)
ME (1)	ME01619B (pt)
MX (1)	MX2011008280A (pt)
NI (1)	NI201100160A (pt)
NZ (1)	NZ595248A (pt)
PE (2)	PE20151281A1 (pt)
PL (1)	PL2398780T3 (pt)
PT (1)	PT2398780E (pt)
RS (1)	RS52851B (pt)
SA (1)	SA110310136B1 (pt)
SG (1)	SG173449A1 (pt)
SI (1)	SI2398780T1 (pt)
SM (1)	SMT201300077B (pt)
SV (1)	SV2011004008A (pt)
TW (1)	TW201039825A (pt)
UA (1)	UA108841C2 (pt)
UY (1)	UY32460A (pt)
WO (1)	WO2010096011A1 (pt)
ZA (1)	ZA201106821B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9108948B2 (en) *	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
SG173312A1 (en) *	2006-06-23	2011-08-29	Abbott Lab	Cyclopropyl amine derivatives as histamin h3 receptor modulators
WO2009024823A2 (en) *	2007-08-22	2009-02-26	Astrazeneca Ab	Oxadiazole derivatives as dgat inhibitors
TW201039825A (en)	2009-02-20	2010-11-16	Astrazeneca Ab	Cyclopropyl amide derivatives 983
US9186353B2 (en)	2009-04-27	2015-11-17	Abbvie Inc.	Treatment of osteoarthritis pain
MX2012009473A (es) *	2010-02-18	2012-09-12	Astrazeneca Ab	Procesos para preparar derivados de ciclopropilamidas e intermedios asociados con estas.
MX2012009537A (es) *	2010-02-18	2012-08-31	Astrazeneca Ab	Formas solidas que comprenden un derivado de ciclopropilamida.
WO2012037258A1 (en)	2010-09-16	2012-03-22	Abbott Laboratories	Processes for preparing 1,2-substituted cyclopropyl derivatives
HUE057460T2 (hu)	2016-03-22	2022-05-28	Merck Sharp & Dohme	Nikotinos acetilkolin receptorok alloszterikus modulátorai
WO2022059779A1 (ja)	2020-09-18	2022-03-24	大日本住友製薬株式会社	アミン誘導体
CN114790186A (zh) *	2021-01-25	2022-07-26	武汉人福创新药物研发中心有限公司	作为ep4拮抗剂的稠环化合物及其制备方法和用途

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL297170A (pt) *	1963-04-04	1900-01-01
NL128365C (pt)	1963-11-05
US3449427A (en) *	1965-06-03	1969-06-10	Smithkline Corp	Aminocyclopropane derivatives of 5h-dibenzo(a,d)cycloheptenes
US3697506A (en)	1970-08-07	1972-10-10	Pfizer	Crystalline alkali metal salts of {60 -carboxybenzylpenicillin and process therefor
US3686335A (en) *	1970-12-21	1972-08-22	Smith Kline French Lab	5-vinyl-5h-di benzo(a,d)cycloheptenes
US4432987A (en)	1982-04-23	1984-02-21	Pfizer Inc.	Crystalline benzenesulfonate salts of sultamicillin
US4547505A (en)	1983-03-25	1985-10-15	Degussa Aktiengesellschaft	N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
CS244821B2 (en)	1983-06-16	1986-08-14	Boehringer Ingelheim Ltd	Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
DE3418167A1 (de)	1984-05-16	1985-11-21	Bayer Ag, 5090 Leverkusen	Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen heteroaryloxyacetamiden
DE3600288A1 (de)	1986-01-08	1987-07-16	Bayer Ag	Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
DE3618004A1 (de)	1986-05-28	1987-12-03	Bayer Ag	Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonyliso(thio)-harnstoff-derivaten
JPH05503517A (ja)	1989-12-18	1993-06-10	バージニア・コモンウェルス・ユニバーシティ	シグマレセプターリガンド及びその用途
US5112818A (en) *	1989-12-29	1992-05-12	Banyu Pharmaceutical Co., Ltd.	2-(2-cyclopropylpyrrolidin-4-ylthio)carbapenhem derivatives
IL102909A0 (en)	1991-08-22	1993-01-31	Monsanto Co	Safening herbicidal pyarazolylsulfonylureas
DE4131139A1 (de)	1991-09-19	1993-03-25	Bayer Ag	Verfahren zur herstellung von 1-fluor-cyclopropan-1-carbonsaeure
DE122005000055I2 (de)	1993-03-12	2008-06-05	Upjohn Co	Kristallines ceftiofur (freie säure)
CN1088062C (zh)	1994-11-23	2002-07-24	纽罗根公司	某些4－氨基甲基－2－取代的咪唑衍生物2－氨基甲基－4－取代的咪唑衍生物新的一族多巴胺受体亚型特异性配体
US5604253A (en)	1995-05-22	1997-02-18	Merck Frosst Canada, Inc.	N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5859246A (en)	1997-01-30	1999-01-12	Neurogen Corporation	1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands
WO1998037077A1 (en)	1997-02-24	1998-08-27	Zymogenetics, Inc.	Calcitonin mimetics
US6160134A (en)	1997-12-24	2000-12-12	Bristol-Myers Squibb Co.	Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
BR9907300A (pt)	1998-01-27	2000-10-24	Aventis Pharm Prod Inc	Inibidores do fator xa oxoaza-heterociclila substituìdos
US6268367B1 (en)	1998-02-23	2001-07-31	Zymogenetics, Inc.	Piperazine derivatives for treating bone deficit conditions
WO2000000492A1 (en)	1998-06-26	2000-01-06	Chugai Seiyaku Kabushiki Kaisha	FINE POWDER OF L-α-AMINOADIPIC ACID DERIVATIVE, ORAL SOLID PREPARATIONS CONTAINING THE SAME, AND METHOD FOR TREATMENT OF BULK POWDERS
WO2000040572A1 (en)	1999-01-08	2000-07-13	Neurogen Corporation	1-phenyl-4-(1-[2-aryl]cyclopropyl) methylpiperazines: dopamine receptor ligands
US6284761B1 (en) *	1999-01-08	2001-09-04	Neurogen Corporation	1-phenyl-4-(1-[2-aryl]cyclopropyl)methylpiperazines: dopamine receptor ligands
EP1186604A4 (en)	1999-06-16	2002-10-23	Takeda Chemical Industries Ltd	Benzazepine derivatives, process for the preparation of the same and uses thereof
AU7715300A (en)	1999-09-27	2001-04-30	Merck & Co., Inc.	Method of preventing osteoporosis
CZ20022332A3 (cs)	2000-01-07	2003-01-15	Transform Pharmaceuticals, Inc.	Sestava vzorků
US6521619B2 (en) *	2000-06-29	2003-02-18	Icos Corporation	Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents
AU2001268724B2 (en)	2000-06-29	2005-06-16	Abbott Laboratories	Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
JP2004525071A (ja)	2000-07-20	2004-08-19	ニューロジェンコーポレイション	カプサイシン受容体リガンド
US6888012B2 (en)	2000-12-25	2005-05-03	Ajinomoto Co., Inc.	Process for producing optically active halohydrin compound
SI1379520T1 (sl) *	2001-02-23	2006-08-31	Merck & Co Inc	N-substituirani nonaril-heterociklicni NMDA/NR2B antagonisti
JP2005502623A (ja)	2001-07-02	2005-01-27	ノボ　ノルディスク　アクティーゼルスカブ	置換ピペラジンおよびジアゼパン
US7262185B2 (en)	2001-08-08	2007-08-28	Takeda Chemical Industries Ltd.	Benzazepine derivative, process for producing the same, and use
CA2457642C (en)	2001-09-26	2009-01-06	Merck & Co., Inc.	Crystalline forms of ertapenem sodium
AU2002363236A1 (en)	2001-10-30	2003-05-12	Millennium Pharmaceuticals, Inc.	Compounds, pharmaceutical compositions and methods of use therefor
US6861432B2 (en) *	2001-11-23	2005-03-01	Schering Aktiengesellschaft	Piperazine derivatives that destabilize androgen receptors
BR0308525A (pt)	2002-03-22	2005-02-01	Lg Life Sciences Ltd	Formas cristalinas
WO2003103666A2 (en)	2002-06-07	2003-12-18	Altana Pharma Ag	Novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones
US20040077618A1 (en) *	2002-10-22	2004-04-22	Bennani Youssef L.	Cycloalkylamides and their therapeutic applications
US20040209858A1 (en) *	2002-10-22	2004-10-21	Bennani Youssef L.	Cycloalkylamides and their therapeutic applications
JPWO2004046110A1 (ja)	2002-11-15	2006-03-16	アステラス製薬株式会社	メラニン凝集ホルモン受容体拮抗剤
JP2006514950A (ja)	2002-12-13	2006-05-18	スミスクラインビーチャムコーポレーション	Ｃｃｒ５拮抗薬としてのシクロプロピル化合物
CA2523431A1 (en)	2003-04-23	2004-11-25	Glaxo Group Limited	Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
CA2524321A1 (en)	2003-05-01	2004-11-18	Bristol-Myers Squibb Company	Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
TWI339206B (en)	2003-09-04	2011-03-21	Vertex Pharma	Compositions useful as inhibitors of protein kinases
ATE464286T1 (de)	2003-12-15	2010-04-15	Japan Tobacco Inc	Cyclopropanderivate und ihre pharmazeutische verwendung
ATE537830T1 (de)	2004-07-06	2012-01-15	Xenon Pharmaceuticals Inc	Nicotinamid derivate und ihre verwendung als therapeutika
TW200621760A (en)	2004-09-09	2006-07-01	Mitsubishi Pharma Corp	2-morpholino-4-pyrimidone compound
EP1805164B9 (en)	2004-09-29	2011-09-07	Mitsubishi Tanabe Pharma Corporation	6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors
HRP20080227T3 (hr)	2004-10-15	2008-06-30	Glaxo Group Limited	Pirolidinski derivati kao ligandi histaminskih receptora
BRPI0517423A (pt)	2004-12-27	2008-10-07	Astrazeneca Ab	composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
EP1844052A1 (en)	2005-01-26	2007-10-17	Pharmacia & Upjohn Company LLC	Thieno[2,3-d]pyrimidine compounds as inhibitors of adp-mediated platelets aggregation
US7790758B2 (en)	2005-02-15	2010-09-07	Glaxo Group Limited	Compounds which potentiate glutamate receptor and uses thereof in medicine
KR101063663B1 (ko)	2005-02-17	2011-09-07	아스텔라스세이야쿠 가부시키가이샤	피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체
JP2008534488A (ja)	2005-03-25	2008-08-28	ファルマシア・アンド・アップジョン・カンパニー・エルエルシー	血小板凝集阻害剤としての４−ピペラジニルチエノ［２，３−ｄ］ピリミジン化合物
WO2006103544A2 (en)	2005-03-28	2006-10-05	Pharmacia & Upjohn Company Llc	4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
WO2006103545A1 (en)	2005-03-28	2006-10-05	Pharmacia & Upjohn Company Llc	4-piperazinylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors
CA2602538A1 (en)	2005-03-28	2006-10-05	Pharmacia & Upjohn Company Llc	4-piperazinothieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors
WO2007011623A1 (en)	2005-07-15	2007-01-25	Schering Corporation	Quinazoline derivatives useful in cancer treatment
TW200740779A (en)	2005-07-22	2007-11-01	Mitsubishi Pharma Corp	Intermediate compound for synthesizing pharmaceutical agent and production method thereof
CA2606004A1 (en)	2005-08-02	2007-02-08	Neurogen Corporation	Dipiperazinyl ketones and related analogues
ATE463481T1 (de) *	2005-09-16	2010-04-15	Janssen Pharmaceutica Nv	Cyclopropylamine als modulatoren des histamin-h3- rezeptors
US8158673B2 (en)	2005-10-27	2012-04-17	Pfizer Inc.	Histamine-3 receptor antagonists
BRPI0618076A2 (pt)	2005-10-31	2011-08-16	Janssen Pharmaceutica Nv	processos para a preparação de derivados de ciclopropil-amida
JP2009524591A (ja)	2005-12-21	2009-07-02	バーテックスファーマシューティカルズインコーポレイテッド	イオンチャネルのモジュレーターとしての複素環誘導体
US8119668B2 (en)	2005-12-23	2012-02-21	Nelson Erik B	Treatment methods employing histamine H3 receptor antagonists, including betahistine
BRPI0707916A2 (pt) *	2006-01-13	2011-05-17	Hoffmann La Roche	compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
CN101384581B (zh)	2006-02-17	2013-09-18	弗·哈夫曼-拉罗切有限公司	作为5ht2/d3调节剂的苯甲酰基-哌啶衍生物
WO2007098536A1 (en)	2006-03-01	2007-09-07	Cementech Pty Ltd	Matrix for masonry elements and method of manufacture thereof
JP2009132621A (ja)	2006-03-13	2009-06-18	Ajinomoto Co Inc	シクロプロピルアミド化合物の製造方法
JP2009530390A (ja)	2006-03-23	2009-08-27	アムゲンインコーポレイティッド	１−フェニルスルホニル−ジアザ複素環アミド化合物およびヒドロキシステロイドデヒドロゲナーゼ調節因子としてのその使用
WO2007138928A1 (ja)	2006-05-26	2007-12-06	Kaneka Corporation	光学活性３－アミノ－２－ヒドロキシプロピオン酸シクロプロピルアミド誘導体およびその塩の製造方法
SG173312A1 (en) *	2006-06-23	2011-08-29	Abbott Lab	Cyclopropyl amine derivatives as histamin h3 receptor modulators
US9108948B2 (en) *	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
WO2008003702A2 (en)	2006-07-03	2008-01-10	Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg	Fused bicyclic compounds interacting with the histamine h4 receptor
US20090247499A1 (en)	2006-08-21	2009-10-01	Fletcher Joan M	Sulfonylated piperazines as cannabinoid-1 receptor modulators
TW200828371A (en)	2006-09-21	2008-07-01	Matsushita Electric Industrial Co Ltd	Chip-type filter
DE102006056526A1 (de)	2006-11-30	2008-06-05	Archimica Gmbh	Verfahren zur stereoselektiven Synthese von chiralen Epoxiden durch ADH-Reduktion von alpha-Abgangsgruppen-substituierten Ketonen und Cyclisierung
US7737149B2 (en)	2006-12-21	2010-06-15	Astrazeneca Ab	N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
WO2008147864A2 (en) *	2007-05-22	2008-12-04	Xenon Pharmaceuticals Inc.	Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
EP2150115B1 (en)	2007-05-23	2013-09-18	Merck Sharp & Dohme Corp.	Cyclopropyl pyrrolidine orexin receptor antagonists
DE602008002598D1 (en) *	2007-06-11	2010-10-28	Hoffmann La Roche	Cyclohexylderivate
WO2009024823A2 (en) *	2007-08-22	2009-02-26	Astrazeneca Ab	Oxadiazole derivatives as dgat inhibitors
ES2460897T3 (es)	2007-10-04	2014-05-14	F. Hoffmann-La Roche Ag	Derivados de ciclopropil aril amida y usos de los mismos
AR070107A1 (es)	2008-01-15	2010-03-17	Lilly Co Eli	R-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida en forma cristalina, composicion farmaceutica que la comprende y su uso para la manufactura de un medicamento util para la prevencion o tratamiento de hiperglicemia
DE102008049371A1 (de)	2008-03-06	2009-09-10	Mühlbauer Ag	Einrichtung mit einem RFID-Transponder in einem elektrisch leitfähigen Gegenstand und Herstellungsverfahren hierfür
US8691804B2 (en)	2008-05-08	2014-04-08	Evotec Ag	Azetidines and cyclobutanes as histamine H3 receptor antagonists
CN102137836B (zh)	2008-07-28	2015-08-26	赛丹思科大学	用于治疗代谢疾病的化合物
CN101462980B (zh)	2009-01-05	2013-01-09	扬州天辰精细化工有限公司	2，6—二氟苯甲酰胺的工业化生产方法
TW201039825A (en)	2009-02-20	2010-11-16	Astrazeneca Ab	Cyclopropyl amide derivatives 983
MX2012009537A (es) *	2010-02-18	2012-08-31	Astrazeneca Ab	Formas solidas que comprenden un derivado de ciclopropilamida.
MX2012009473A (es) *	2010-02-18	2012-09-12	Astrazeneca Ab	Procesos para preparar derivados de ciclopropilamidas e intermedios asociados con estas.

2010
- 2010-02-12 TW TW099104778A patent/TW201039825A/zh unknown
- 2010-02-17 SA SA110310136A patent/SA110310136B1/ar unknown
- 2010-02-19 PE PE2015001189A patent/PE20151281A1/es not_active Application Discontinuation
- 2010-02-19 HR HRP20130579AT patent/HRP20130579T1/hr unknown
- 2010-02-19 PT PT107440281T patent/PT2398780E/pt unknown
- 2010-02-19 AU AU2010216454A patent/AU2010216454B2/en not_active Ceased
- 2010-02-19 CA CA2752796A patent/CA2752796A1/en not_active Abandoned
- 2010-02-19 WO PCT/SE2010/050191 patent/WO2010096011A1/en not_active Ceased
- 2010-02-19 PE PE2011001527A patent/PE20120063A1/es not_active Application Discontinuation
- 2010-02-19 PL PL10744028T patent/PL2398780T3/pl unknown
- 2010-02-19 AR ARP100100499A patent/AR075531A1/es unknown
- 2010-02-19 US US12/708,550 patent/US8993577B2/en not_active Expired - Fee Related
- 2010-02-19 UA UAA201109215A patent/UA108841C2/ru unknown
- 2010-02-19 EA EA201190140A patent/EA020093B1/ru not_active IP Right Cessation
- 2010-02-19 UY UY0001032460A patent/UY32460A/es not_active Application Discontinuation
- 2010-02-19 DK DK10744028.1T patent/DK2398780T3/da active
- 2010-02-19 NZ NZ595248A patent/NZ595248A/en not_active IP Right Cessation
- 2010-02-19 SG SG2011053477A patent/SG173449A1/en unknown
- 2010-02-19 SI SI201030257T patent/SI2398780T1/sl unknown
- 2010-02-19 ES ES10744028T patent/ES2416464T3/es active Active
- 2010-02-19 EP EP10744028.1A patent/EP2398780B1/en active Active
- 2010-02-19 KR KR1020117019311A patent/KR20110126628A/ko not_active Withdrawn
- 2010-02-19 MX MX2011008280A patent/MX2011008280A/es active IP Right Grant
- 2010-02-19 BR BRPI1007817A patent/BRPI1007817A2/pt not_active IP Right Cessation
- 2010-02-19 RS RS20130280A patent/RS52851B/sr unknown
- 2010-02-19 CN CN201410557796.0A patent/CN104398516A/zh active Pending
- 2010-02-19 EA EA201490268A patent/EA201490268A1/ru unknown
- 2010-02-19 ME MEP-2013-74A patent/ME01619B/me unknown
- 2010-02-19 JP JP2011551039A patent/JP5666480B2/ja not_active Expired - Fee Related
- 2010-02-19 CN CN201080017452.0A patent/CN102405213B/zh not_active Expired - Fee Related
2011
- 2011-07-25 IL IL214277A patent/IL214277A/en not_active IP Right Cessation
- 2011-07-29 CO CO11095921A patent/CO6400219A2/es active IP Right Grant
- 2011-08-19 CR CR20110447A patent/CR20110447A/es unknown
- 2011-08-19 SV SV2011004008A patent/SV2011004008A/es unknown
- 2011-08-19 DO DO2011000270A patent/DOP2011000270A/es unknown
- 2011-08-19 NI NI201100160A patent/NI201100160A/es unknown
- 2011-08-19 EC EC2011011280A patent/ECSP11011280A/es unknown
- 2011-08-19 CU CU20110161A patent/CU20110161A7/es unknown
- 2011-08-19 HN HN2011002261A patent/HN2011002261A/es unknown
- 2011-09-19 ZA ZA2011/06821A patent/ZA201106821B/en unknown
2013
- 2013-07-04 SM SM201300077T patent/SMT201300077B/xx unknown
2014
- 2014-02-06 CU CU2014000013A patent/CU20140013A7/es unknown
- 2014-12-09 JP JP2014248499A patent/JP2015071634A/ja active Pending
2015
- 2015-02-24 US US14/630,530 patent/US20150164889A1/en not_active Abandoned
- 2015-02-24 US US14/630,514 patent/US20150164888A1/en not_active Abandoned
- 2015-09-11 HK HK15108903.2A patent/HK1208348A1/xx unknown

Also Published As

Publication number	Publication date
AU2010216454B2 (en)	2013-05-02
MX2011008280A (es)	2011-08-24
HK1164863A1 (en)	2012-09-28
ZA201106821B (en)	2012-06-26
PE20151281A1 (es)	2015-10-04
UY32460A (es)	2010-09-30
NI201100160A (es)	2012-03-15
IL214277A (en)	2015-08-31
IL214277A0 (en)	2011-09-27
HN2011002261A (es)	2014-07-31
CA2752796A1 (en)	2010-08-26
SI2398780T1 (sl)	2013-08-30
DOP2011000270A (es)	2012-08-31
AU2010216454A1 (en)	2011-08-25
SG173449A1 (en)	2011-09-29
US8993577B2 (en)	2015-03-31
EP2398780A4 (en)	2012-09-19
ES2416464T3 (es)	2013-08-01
CU20110161A7 (es)	2012-02-15
US20150164889A1 (en)	2015-06-18
NZ595248A (en)	2014-01-31
SMT201300077B (it)	2013-09-06
ECSP11011280A (es)	2011-09-30
HRP20130579T1 (en)	2013-07-31
SV2011004008A (es)	2012-01-06
EA201490268A1 (ru)	2015-07-30
CU20140013A7 (es)	2014-04-24
JP5666480B2 (ja)	2015-02-12
EP2398780A1 (en)	2011-12-28
TW201039825A (en)	2010-11-16
CR20110447A (es)	2011-09-19
SA110310136B1 (ar)	2014-01-14
PT2398780E (pt)	2013-06-25
CN104398516A (zh)	2015-03-11
CN102405213B (zh)	2014-11-19
ME01619B (me)	2014-09-20
US20100216812A1 (en)	2010-08-26
EP2398780B1 (en)	2013-04-17
AR075531A1 (es)	2011-04-06
JP2015071634A (ja)	2015-04-16
KR20110126628A (ko)	2011-11-23
PL2398780T3 (pl)	2013-08-30
PE20120063A1 (es)	2012-03-04
UA108841C2 (ru)	2015-06-25
CO6400219A2 (es)	2012-03-15
EA201190140A1 (ru)	2012-03-30
WO2010096011A1 (en)	2010-08-26
HK1208348A1 (en)	2016-03-04
US20150164888A1 (en)	2015-06-18
DK2398780T3 (da)	2013-07-01
EA020093B1 (ru)	2014-08-29
RS52851B (sr)	2013-12-31
JP2012518634A (ja)	2012-08-16
CN102405213A (zh)	2012-04-04

Publication	Publication Date	Title
BRPI1007817A2 (pt)	2017-05-30	composto, composição farmacêutica, uso de um composto, e , métodos para tratar déficit congnitivo na esquisofrenia, doença de alzheimer, obesidade, narcolepsia, dor e distúrbio de hiperatividade e déficit de atenção em um animal de sangue quente, e para tratar um distúrbio em que a modulação do receptor da histamina h3 é benéfica.
BRPI0821168A2 (pt)	2015-10-27	anticorpo, hibridoma, e, métodos para tratar doenças em um paciente e para tratar um paciente de transplante
BRPI0816175A2 (pt)	2015-02-24	Composições adequadas para tratamento de doença, distúrbio ou condição da espinha.
BR112013002250A2 (pt)	2016-05-24	composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto.
BRPI0919876A2 (pt)	2015-08-18	Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.
BRPI0814825A2 (pt)	2015-02-03	Composto, processo para a preparação do composto, composição farmacêutica que o compreende, seu uso e métodos para o tratamento ou profilaxia de diabetes, obesidade, distúrbios de alimentação ou dislipimedia e diabetes do tipo ii
BRPI0908428A2 (pt)	2015-12-08	uso de ranozalina para tratar a dor.
PT2426148E (pt)	2015-10-26	Anticorpo anti-rá-il-3 para se utilizar no tratamento de tumores do sangue
BRPI1007636A2 (pt)	2015-09-01	Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI1012993A2 (pt)	2018-01-16	"uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI0818426A2 (pt)	2017-06-13	produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI1009381A2 (pt)	2016-06-21	compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0807987A2 (pt)	2014-06-24	Terapia de combinação para tratamento de distúrbios imunes.
BRPI0815760A2 (pt)	2014-09-30	Composição dermatológica injetável para o tratamento de rugas
BR112012003464A2 (pt)	2015-09-08	composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BR112012010670A2 (pt)	2016-04-12	métodos para tratamento de distúrbio de défict de atenção/hiperatividade
BRPI1013777A8 (pt)	2017-09-19	Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.
BRPI0924203A2 (pt)	2016-01-19	composição cosmética em forma de espuma, produto, kit, e, processo para cuidar e/ou maquiar o corpo.
BRPI0815493A2 (pt)	2015-02-10	Composto, uso de um composto, composição faramcêutica, método para a terapia de dor, e, processo para preparar um composto.
BRPI0811059A2 (pt)	2017-05-09	combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
CR9019A (es)	2008-10-28	Utilizacion de la agomelatina para la obtencion de medicamentos destinados al tratamiento del trastorno de ansiedad generalizada

Legal Events

Date	Code	Title	Description
2017-06-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2017-09-19	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]